Completed PHASE1 INTERVENTIONAL 6-arm NCT01390428

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172)

Sponsor: Merck Sharp & Dohme LLC

Conditions Hepatitis C

Interventions Grazoprevir

Updated 9 times since 2017 Last updated: Aug 16, 2018 Started: Jul 28, 2011 Primary completion: Sep 5, 2014 Completion: Sep 12, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatitis C and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Dec 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.